Comparable stake leader
PharmAla Biotech Holdings Inc.
SEC ownership of JUPITER NEUROSCIENCES, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001679628.
Disclosed value leader
Christer Rosen
Comparable rows
15/27
Latest evidence
21 Aug 2026
- Public ticker
- JUNS on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PharmAla Biotech Holdings Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
15 of 27
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PharmAla Biotech Holdings Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
21 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001679628
- Issuer location
- Jupiter, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of JUPITER NEUROSCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PharmAla Biotech Holdings...
Disclosed value leader
Christer Rosen
Comparable rows
15/27
Latest evidence
21 Aug 2026
13D/G
13F
3/4/5
Lead comparable stake: 17%
12 rows are not safely comparable across share classes.
13D/G row: PharmAla Biotech Holdings Inc.
Showing 1-8 of 27 holder rows.
Quick read
PharmAla Biotech Holdings Inc. leads the comparable SEC ownership view at 17%.
15 of 27 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PharmAla Biotech Holdings Inc.'s linked filing trail.
Comparable ownership
Top 5
PharmAla Biotech Holdings Inc.
17%
Orca Capital AG
3.3%
JANE STREET GROUP, LLC
69%
Virtu Financial LLC
30%
GEODE CAPITAL MANAGEMENT, LLC
20%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 27 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PharmAla Biotech Holdings Inc. |
13D/G
|
17%
|
$10,629
132,867 shares
|
$0 | 20 Aug 2026 |
| Orca Capital AG |
13D/G
|
3.3%
|
—
39,945 shares
|
$0 | 21 Aug 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
69%
|
$114,253
533,395 shares
|
— | 30 Jun 2026 |
| Virtu Financial LLC |
13F
Company
|
30%
|
$50,000
231,240 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
20%
|
$33,441
156,127 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
17%
|
$27,401
128,042 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
11%
|
$18,013
84,173 shares
|
— | 30 Jun 2026 |
| XTX Topco Ltd |
13F
Company
|
4.3%
|
$7,019
32,770 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 25 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to JUPITER NEUROSCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Christer Rosen
Net 12M change
$0
Latest report
31 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christer Rosen | CEO and Chairman, Director | $11,300,469 | Filing P/S | 02 Jun 2026 | ||
| Ph.D. Marshall Hayward | Chief Scientific Officer, Director | $778,720 | Mixed | 02 Jun 2026 | ||
| Alexander Gustaf Erik Rosen | Chief Administrative Officer | $160,526 | Mixed | 02 Jun 2026 | ||
| Alison D. Silva | President and COO, Director | $116,611 | Filing P/S | 02 Jun 2026 | ||
| Saleem Elmasri | Chief Financial Officer | $74,187 | Mixed | 02 Jun 2026 | ||
| Allison W. Brady | Director | $60,900 | Mixed | 02 Jun 2026 | ||
| Weis Holger | Director | $55,298 | Mixed | 02 Jun 2026 | ||
| Nicholas H. Hemmerly | Director | $24,843 | Mixed | 02 Jun 2026 | ||
| Julie B. Kampf | Director | $21,547 | Mixed | 02 Jun 2026 | ||
| Andrew J. Cutler | Director | Mixed | 31 Jul 2026 | |||
| Tomas J. Philipson | Director | Mixed | 26 Jun 2026 | |||
| Claes Robert Wahlestedt | 10%+ Owner | Mixed | 08 Nov 2024 |
Recent insider transactions for JUPITER NEUROSCIENCES, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrew J. Cutler | JUNS | Stock Option (right to buy) | Award | 472,222 | 472,222 | 31 Jul 2026 | Direct | |||
| Tomas J. Philipson | JUNS | Stock Option (right to buy) | Award | 536,428 | 536,428 | 29 Jun 2026 | Direct | |||
| Allison W. Brady | JUNS | Stock Option | Award | 100,000 | 100,000 | 02 Jun 2026 | Direct | |||
| Saleem Elmasri | JUNS | Stock Option | Award | 525,565 | 525,565 | 02 Jun 2026 | Direct | |||
| Christer Rosen | JUNS | Stock Option | Award | 747,783 | 747,783 | 02 Jun 2026 | Direct | |||
| Nicholas H. Hemmerly | JUNS | Stock Option | Award | 100,000 | 100,000 | 02 Jun 2026 | Direct | |||
| Julie B. Kampf | JUNS | Stock Option | Award | 100,000 | 100,000 | 02 Jun 2026 | Direct | |||
| Alison D. Silva | JUNS | Stock Option | Award | 1,027,304 | 1,027,304 | 02 Jun 2026 | Direct | |||
| Ph.D. Marshall Hayward | JUNS | Stock Option | Award | 259,231 | 259,231 | 02 Jun 2026 | Direct | |||
| Holger Weis | JUNS | Stock Option | Award | 100,000 | 100,000 | 02 Jun 2026 | Direct | |||
| Alexander Gustaf Erik Rosen | JUNS | Stock Option | Award | 341,843 | 341,843 | 02 Jun 2026 | Direct | |||
| Marshall A. Hayward | JUNS | Common Stock | Options Exercise | 8.12% | 225,000 | 2,995,077 | 02 Mar 2026 | Direct | ||
| Marshall A. Hayward | JUNS | Stock Option (right to buy) | Options Exercise | -100% | -225,000 | 0 | 02 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.